Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.2)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 7, October, p. 1091–1094

doi: 10.17219/acem/66372

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Usefulness of carcinoembryonic antigen in the diagnosis of small cell lung cancer combined with adenocarcinoma

Lei Lei1,2,A,B,C,D, Qixun Chen1,B, Zeng Wang3,C, Na Han2,B, Bo Chen4,B, Jing Qin2,B, Hong-Yang Lu1,2,A,E,F

1 Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, China

2 Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China

3 Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, China

4 Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, China

Abstract

Background. Small cell lung cancer (SCLC) includes pure SCLC and SCLC combined with other pathologies (C-SCLC). C-SCLC accounts for about 28% of all SCLCs subjected to surgical resection, but only about 1%–3% of C-SCLCs are detected by biopsy. Since less than 5% of SCLC patients are eligible for surgery, it is necessary to develop alternative methods for the detection of C-SCLC.
Objectives. We determined whether serum carcinoembryonic antigen (CEA) levels, which are usually elevated in lung adenocarcinomas, could be used to differentiate between pure SCLC and SCLC combined with adenocarcinoma.
Material and Methods. We reviewed the records of 41 SCLC patients (35 with pure SCLC, 6 with C-SCLC) who underwent surgical resection between 2000 and 2014 in Zhejiang Cancer Hospital. Their preoperative serum CEA levels were noted, and the relationship between CEA level and the type of SCLC was analyzed.
Results. Serum CEA levels >6ng/mL were found more frequently in C-SCLC patients than in pure SCLC patients (p = 0.031). No such difference was observed when a CEA cut-off of 5ng/mL was used (p = 0.316).
Conclusion. A preoperative serum CEA of >6ng/mL may be used as a reference in the diagnosis of SCLC combined with adenocarcinoma.

Key words

diagnosis, small cell lung cancer (SCLC), carcinoembryonic antigen (CEA), adenocarcinoma

References (24)

  1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–4544.
  2. Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2013;14:113–119.
  3. Wang X, Jiang R, Li K. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys. 2014;69:633–640.
  4. Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res. 2008;14:6092–6096.
  5. Lu HY, Wang XJ, Mao WM. Targeted therapies in small cell lung cancer. Oncol Lett. 2013;5:3–11.
  6. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607–612.
  7. Fraire AE, Johnson EH, Yesner R, Zhang XB, Spjut HJ, Greenberg SD. Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol. 1992;23:520–528.
  8. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): A clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–1197.
  9. Rostad H, Naalsund A, Jacobsen R, et al. Small cell lung cancer in Norway: Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg. 2004;26:782–786.
  10. Koletsis EN, Prokakis C, Karanikolas M, Apostolakis E, Dougenis D. Current role of surgery in small cell lung carcinoma. J Cardiothorac Surg. 2009;4:30.
  11. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–484.
  12. Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: A systematic review of the literature with meta-analysis. BMC Cancer. 2001;1:5.
  13. Lu HY, Mao WM, Cheng QY, et al. Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett. 2012;3:1288–1292.
  14. Wagner PL, Kitabayashi N, Chen YT, Saqi A. Combined small cell lung carcinomas: Genotypic and immunophenotypic analysis of the separate morphologic components. Am J Clin Pathol. 2009;131:376–382.
  15. Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209–218.
  16. Wang CY, Huang MS, Huang MH, Lee HC, Hsu HS. Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer. J Surg Res. 2010;163:e45–50.
  17. Yang ZM, Ding XP, Pen L, Mei L, Liu T. Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers. Asian Pac J Cancer Prev. 2014;15:3451–3455.
  18. Arrieta O, Villarreal-Garza C, Martinez-Barrera L, et al. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: A prospective cohort study. BMC Cancer. 2013;13:254.
  19. Li CG, Huang XE, Xu L, Li Y, Lu YY. Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2012;13:301–304.
  20. Okada M, Nishio W, Sakamoto T, et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg. 2004;78:1004–1009.
  21. Cullen KJ, Stevens DP, Frost MA, Mackay IR. Carcinoembryonic antigen (CEA), smoking, and cancer in a longitudinal population study. Aust N Z J Med. 1976;6:279–283.
  22. Pezzuto A, Spoto C, Vincenzi B, Tonini G. Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level. J Comp Eff Res. 2013;2:335–343.
  23. Hanna NH, Einhorn LH. Small-cell lung cancer: State of the art. Clin Lung Cancer. 2002;4:87–94.
  24. Guo Y, Qu L, Shao M, Wang X, Sun H, Ma K. A case report of combined small cell lung cancer with EGFR mutation and treatment experience. Zhongguo Fei Ai Za Zhi. 2014;17:511–514.
© Wroclaw Medical University